22 related articles for article (PubMed ID: 30840281)
1. Expression levels of miR-205 and miR-506 in colon cancer tissues and their relationships with clinicopathological features.
Jing N; Yin L; Sun J; Cao Z; Mao W
Oncol Lett; 2018 Oct; 16(4):4331-4336. PubMed ID: 30214569
[TBL] [Abstract][Full Text] [Related]
2. miR-107 and miR-126 and Risk of Breast Cancer: A Case-Control Study.
Gupta P; Sambyal V; Bali JS; Guleria K; Uppal MS; Sudan M
Genet Test Mol Biomarkers; 2024 Apr; 28(4):165-168. PubMed ID: 38487920
[No Abstract] [Full Text] [Related]
3. Identification of MicroRNAs Associated with Histological Grade in Early-Stage Invasive Breast Cancer.
Kurozumi S; Seki N; Narusawa E; Honda C; Tokuda S; Nakazawa Y; Yokobori T; Katayama A; Mongan NP; Rakha EA; Oyama T; Fujii T; Shirabe K; Horiguchi J
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203206
[TBL] [Abstract][Full Text] [Related]
4. Long non-coding RNA MEG3 acts as a suppressor in breast cancer by regulating miR-330/CNN1.
Yi D; Wang Z; Yang H; Wang R; Shi X; Liu Z; Xu F; Lu Q; Chu X; Sang J
Aging (Albany NY); 2024 Jan; 16(2):1318-1335. PubMed ID: 38240701
[TBL] [Abstract][Full Text] [Related]
5. MALAT1-miRNAs network regulate thymidylate synthase and affect 5FU-based chemotherapy.
Matuszyk J
Mol Med; 2022 Aug; 28(1):89. PubMed ID: 35922756
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, Safety, and Prognosis of Sequential Therapy with Tamoxifen and Letrozole versus Letrozole Monotherapy for Breast Carcinoma.
Lu X; Qian C
Comput Math Methods Med; 2022; 2022():1979254. PubMed ID: 35464999
[TBL] [Abstract][Full Text] [Related]
7. miR-143-5p suppresses breast cancer progression by targeting the HIF-1α-related GLUT1 pathway.
Xu J; Li X; Zhang P; Luo J; Mou E; Liu S
Oncol Lett; 2022 May; 23(5):147. PubMed ID: 35350590
[TBL] [Abstract][Full Text] [Related]
8. The Role of MicroRNA as Clinical Biomarkers for Breast Cancer Surgery and Treatment.
Davey MG; Davies M; Lowery AJ; Miller N; Kerin MJ
Int J Mol Sci; 2021 Aug; 22(15):. PubMed ID: 34361056
[TBL] [Abstract][Full Text] [Related]
9. Correlation Between Raf/MEK/ERK Signaling Pathway and Clinicopathological Features and Prognosis for Patients With Breast Cancer Having Axillary Lymph Node Metastasis.
Shao GL; Wang MC; Fan XL; Zhong L; Ji SF; Sang G; Wang S
Technol Cancer Res Treat; 2018 Jan; 17():1533034617754024. PubMed ID: 29529946
[TBL] [Abstract][Full Text] [Related]
10. Correlations of the MiR-330 expression with the pathogenesis and prognosis of breast cancer.
Zhang HL; Wang XX; Zhang F
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1584-1590. PubMed ID: 30840281
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-21 as an indicator of aggressive phenotype in breast cancer.
Ozgün A; Karagoz B; Bilgi O; Tuncel T; Baloglu H; Kandemir EG
Onkologie; 2013; 36(3):115-8. PubMed ID: 23485999
[TBL] [Abstract][Full Text] [Related]
12. Low levels of serum miR-99a is a predictor of poor prognosis in breast cancer.
Li J; Song ZJ; Wang YY; Yin Y; Liu Y; Nan X
Genet Mol Res; 2016 Aug; 15(3):. PubMed ID: 27706621
[TBL] [Abstract][Full Text] [Related]
13. [Correlation of miR-195 with invasiveness and prognosis of breast cancer].
Song CG; Wu XY; Wang C; Fu FM; Shao ZM
Zhonghua Wai Ke Za Zhi; 2012 Apr; 50(4):353-6. PubMed ID: 22800791
[TBL] [Abstract][Full Text] [Related]
14. Association of chemotactic factor receptor 5 gene with breast cancer.
Zhang Y; Meng FY; Li WL; Zhou CX; Guan Z; Fan HY
Genet Mol Res; 2013 Nov; 12(4):5289-300. PubMed ID: 24301790
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
